Earnings release · VRTX
Vertex Reports Second Quarter 2026 Financial Results
Vertex Pharmaceuticals Inc / Ma · Filed · SEC Form 8-K, Item 2.02
Vertex Pharmaceuticals Inc / Ma company page Original on SEC.gov ↗
Revenue
$3.33 billion
+12% vs a year ago
EPS
$85.00
not detected
Guidance
raisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete.
Please read the original before relying on any figure. Not investment advice.
Why it matters
Revenue increased 12% year on year to $3.33 billion, and EPS was $85.00. Management raised its outlook, and guidance changes often matter more to the market than the quarter just reported because they reflect expectations for the periods ahead.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
What the company states
Revenue
$3.33 billion +12% vs a year ago
…Total revenue increased 12% to $3.33 billion compared to the second quarter of 2025, primarily driven…
EPS
$85.00
…a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 bi…
Guidance
Guidance raised
…— Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — — Continued progress across research and develop…
Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.